The patient received three once weekly doses of FT500, and the treatment cycle was well-tolerated with no dose-limiting toxicities or serious adverse events reported during the initial 28-day observation period, the company said in a statement.
FT500 is a natural killer cell cancer immunotherapy. It is the first-ever cell therapy derived from an "induced pluripotent stem cell" (iPSC) administered to a patient in the US.
The company said that new preclinical data of universal, off-the-shelf, iPSC-derived NK cell product candidates -- FT516 and FT596 -- have also been highlighted at the 2019 AACR (American Association for Cancer Research) annual meeting.
Price: 17.56, Change: -0.01, Percent Change: -0.06
|Avaya Surges 11% on Speculation of Rival Buyout Offe...|
|Correction: --(KSS) KOHLS CORP Q2 Total Revenue $4.43B|
|Correction: Kohl's Q2 Tops Estimates on EPS, Net Sal...|
|Clear Channel Outdoor Climbs 6% on More Insider Purc...|
|Market Chatter: Facebook's Libra Under Investigation...|